%0 Journal Article %A Rongqing Zhao %A Maohua Li %A Hao Song %A Jianxin Chen %A Wenlin Ren %A Yingmei Feng %A Jinwen Song %A Ya Peng %A Bin Su %A Xianghua Guo %A Yanjun Wang %A Jingong Chen %A Jianli Li %A Hunter Sun %A Zhonghu Bai %A WenJing Cao %A Jin Zhu %A Qinlu Zhang %A Yufei Sun %A Sean Sun %A Xinkun Mao %A Junchi Su %A Hui Chen %A Ailiang He %A Ronghua Jin %A Le Sun %T Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins %D 2020 %R 10.1101/2020.03.26.20042184 %J medRxiv %P 2020.03.26.20042184 %X WHO has declared COVID-19 a pandemic with more than 300,000 confirmed cases and more than 14,000 deaths. There is urgent need for accurate and rapid diagnostic kits. Here we report the development and validation of a COVID-19/SARS-CoV-2 S1 serology ELISA kit for the detection of total anti-virus antibody (IgG+IgM) titers in sera from either the general population or patients suspected to be infected. For indirect ELISA, CHO-expressed recombinant full length SARS-CoV-2-S1 protein with 6* His tag was used as the coating antigen to capture the SARS-CoV-2-S1 antibodies specifically. The specificity of the ELISA kit was determined to be 97.5%, as examined against total 412 normal human sera including 257 samples collected prior to the outbreak and 155 collected during the outbreak. The sensitivity of the ELISA kit was determined to be 97.5% by testing against 69 samples from hospitalized and/or recovered COVID-19 patients. The overall accuracy rate reached 97.3%. Most importantly, in one case study, the ELISA test kit was able to identify an infected person who had previously been quarantined for 14 days after coming into contact with a confirmed COVID-19 patient, and discharged after testing negative twice by nucleic acid test. With the assays developed here, we can screen millions of medical staffs in the hospitals and people in residential complex, schools, public transportations, and business parks in the epidemic centers of the outbreaks to fish out the “innocent viral spreaders”, and help to stop the further spreading of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Research Grants from Beijing Science and Technology Commission, and Bill & Melinda Gates Foundation to Le Sun. This work was also supported by the National Natural Science Foundation of China (NSFC) (81702015), and the National Science and Technology Major Project (2018ZX10733403) to H.S.We thank Professor Wenjie Tan from National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention for providing the sequences of SARS-CoV-2 S1 protien.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request. %U https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.26.20042184.full.pdf